![Joanne Soundy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Joanne Soundy
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Public Company | Miscellaneous Commercial Services | 7 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Joanne Soundy
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
University of Cambridge | College/University | Doctorate Degree Doctorate Degree | |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Avacta Life Sciences Ltd.
![]() Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
ReNeuron Ltd.
![]() ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Biotechnology | Director/Board Member | |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Founder | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Gammadelta Therapeutics Ltd.
![]() Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Iksuda Therapeutics Ltd.
![]() Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | Biotechnology | Director/Board Member | |
SAREUM HOLDINGS PLC | Miscellaneous | Director/Board Member | |
The Club Cricket Organisation Ltd. | Director/Board Member | ||
Ossianix Uk Ltd. | Director/Board Member | ||
European Molecular Biology Organization | Corporate Officer/Principal | ||
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
IMMUNOCORE HOLDINGS PLC | Biotechnology | Chief Tech/Sci/R&D Officer | |
Temple University (Pennsylvania) | College/University | Undergraduate Degree | |
University of Pennsylvania | College/University | Doctorate Degree | |
RUBIUS THERAPEUTICS | Biotechnology | Chief Tech/Sci/R&D Officer | |
Tmunity Therapeutics, Inc.
![]() Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Cytoimmune Therapeutics, Inc.
![]() Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Biotechnology | Chief Executive Officer | |
ABCAM PLC | Biotechnology | Comptroller/Controller/Auditor | |
BliNK Biomedical SAS
![]() BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Biotechnology | Director/Board Member | |
The European Molecular Biology Laboratory | College/University | Corporate Officer/Principal | |
The Brigham & Women's Hospital, Inc.
![]() The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal | |
Dana-Farber Cancer Institute, Inc.
![]() Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal | |
IMMUNOGEN, INC. | Biotechnology | Director/Board Member | |
Harvard College | College/University | Undergraduate Degree | |
Harvard Medical School | College/University | Doctorate Degree | |
GLYCOMIMETICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
American Cancer Society New England Division, Inc. | Director/Board Member | ||
ATYR PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member | |
RENEURON GROUP PLC | Pharmaceuticals: Major | Director/Board Member | |
CANbridge Life Sciences Ltd.
![]() CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
American Cancer Society, Inc.
![]() American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Walden Biosciences, Inc.
![]() Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member | |
University of Glasgow | College/University | Undergraduate Degree | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member | |
University of Oxford | College/University | Undergraduate Degree | |
Ossianix, Inc.
![]() Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Generic | Chairman | |
Towson University | College/University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 23 |
Vereinigtes Königreich | 18 |
Deutschland | 3 |
Frankreich | 2 |
China | 2 |
Sektoral
Health Technology | 26 |
Consumer Services | 10 |
Health Services | 4 |
Commercial Services | 3 |
Miscellaneous | 2 |
Operativ
Director/Board Member | 27 |
Chief Tech/Sci/R&D Officer | 10 |
Corporate Officer/Principal | 10 |
Independent Dir/Board Member | 9 |
Undergraduate Degree | 5 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Michael Owen | 20 |
Mark Goldberg | 17 |
Christina Coughlin | 7 |
Fiona McLaughlin | 3 |
Fran Mullen | 3 |
Chris Miller | 1 |
Rob Ford | 1 |
- Börse
- Insiders
- Joanne Soundy
- Unternehmensverbindungen